Literature DB >> 2590997

Uptake and metabolism of iproplatin in murine L1210 cells.

L Pendyala1, J R Walsh, M M Huq, A V Arakali, J W Cowens, P J Creaven.   

Abstract

Iproplatin is structurally unique among the platinum (Pt) agents in the clinic because it is a quadrivalent complex. On the basis of the redox parameters for the Pt(IV) and Pt(II) oxidation states in a chloride system, it has been suggested that Pt(IV) complexes will be reduced to Pt(II) complexes in a biological environment. To test this hypothesis, uptake and metabolism studies of [14C]-iproplatin were carried out in L1210 cells. The L1210 cells raised in DBA2/J mice were incubated in vitro with 50 and 100 microM [14C]-iproplatin at 37 degrees C in Hanks' balanced salt solution, and total uptake and radioactivity associated with acid-insoluble fractions were measured for up to 3 h. Under these conditions, the uptake of iproplatin was linear with time and increased with increasing concentrations of iproplatin in the medium. At all times measured, greater than 35% of radioactivity was associated with the acid-insoluble fraction, suggesting binding to macromolecules. The [14C]-labelled compounds in neutralized acid extracts of cells were separated by reverse-phase high-performance liquid chromatography (HPLC). Three labelled compounds were detected; based on chromatographic elution times, they appeared to be iproplatin, cis-dichloro-bis-isopropylamine platinum(II) (CIP), the reduction product of iproplatin, and a third compound more polar than iproplatin and CIP. The finding of free CIP and the macromolecular binding of radioactivity in the cells suggests that iproplatin is reduced intracellularly.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2590997     DOI: 10.1007/bf00694332

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

Review 1.  Platinum antitumour agents.

Authors:  J C Dabrowiak; W T Bradner
Journal:  Prog Med Chem       Date:  1987

Review 2.  Antitumor activity of platinum complexes.

Authors:  J Drobník
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

3.  Effect of renal function impairment of iproplatin pharmacokinetics and relation to toxicity.

Authors:  L Pendyala; S Madajewicz; P J Creaven
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

4.  Platinum(IV) antitumor agents.

Authors:  E E Blatter; J F Vollano; B S Krishnan; J C Dabrowiak
Journal:  Prog Clin Biol Res       Date:  1985

5.  Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer.

Authors:  H Anderson; J Wagstaff; D Crowther; R Swindell; M J Lind; J McGregor; M S Timms; D Brown; P Palmer
Journal:  Eur J Cancer Clin Oncol       Date:  1988-09

6.  Studies on the human metabolism of iproplatin.

Authors:  L Pendyala; B S Krishnan; J R Walsh; A V Arakali; J W Cowens; P J Creaven
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  Identification of cis-dichloro-bis-isopropylamine platinum(II) as a major metabolite of iproplatin in humans.

Authors:  L Pendyala; J W Cowens; G B Chheda; S P Dutta; P J Creaven
Journal:  Cancer Res       Date:  1988-06-15       Impact factor: 12.701

8.  Pharmacokinetics of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV (CHIP) in patients with advanced cancer.

Authors:  L Pendyala; W Greco; J W Cowens; S Madajewicz; P J Creaven
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

9.  Interaction of the antitumor agents cis,cis,trans-PtIV(NH3)2Cl2(OH)2 and cis,cis,trans-PtIV[(CH3)2CHNH2]2Cl2(OH)2 and their reduction products with PM2 DNA.

Authors:  E E Blatter; J F Vollano; B S Krishnan; J C Dabrowiak
Journal:  Biochemistry       Date:  1984-10-09       Impact factor: 3.162

10.  Activity of JM9 in advanced ovarian cancer: a phase I-II trial.

Authors:  V H Bramwell; D Crowther; S O'Malley; R Swindell; R Johnson; E H Cooper; N Thatcher; A Howell
Journal:  Cancer Treat Rep       Date:  1985-04
  10 in total
  4 in total

1.  DNA binding of iproplatin and its divalent metabolite cis-dichloro-bis-isopropylamine platinum (II).

Authors:  L Pendyala; A V Arakali; P Sansone; J W Cowens; P J Creaven
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Intracellular glutathione and cytotoxicity of platinum complexes.

Authors:  L Pendyala; P J Creaven; R Perez; J R Zdanowicz; D Raghavan
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

3.  Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels.

Authors:  F I Raynaud; D E Odell; L R Kelland
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

4.  Comparison of the effects of the oral anticancer platinum(IV) complexes oxoplatin and metabolite cis-diammine-tetrachlorido-platinum(IV) on global gene expression of NCI-H526 cells.

Authors:  Ulrike Olszewski; Ernst Ulsperger; Klaus Geissler; Gerhard Hamilton
Journal:  J Exp Pharmacol       Date:  2011-04-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.